Bevacizumab versus ziv-aflibercept in branch retinal vein occlusion
Loading...
Date
2019-07-07
Journal Title
Journal ISSN
Volume Title
Publisher
Indian Journal of Ophthalmology
Abstract
PURPOSE:
To compare the effectiveness of treatment with intravitreal bevacizumab (IVB) and ziv-aflibercept (IVZ) in patients with macular edema (ME) post-branch retinal vein occlusion (BRVO).
METHODS:
Patients with treatment naïve ME post-BRVO were included retrospectively if they received either IVB (0.05 ml/1.25 mg) or IVZ (0.05 ml/1.25 mg) monotherapy with a follow up of 12 months.
RESULTS:
Thirty-two and 17 eyes received IVB and IVZ, respectively. The mean improvement in best corrected visual acuity (BCVA) was 0.36 ± 0.3 logarithm of minimum angle of resolution (logMAR) in the IVB group and 0.27 ± 0.3 in the IVZ group (P = 0.35). The mean change in central macular thickness was 178.9 ± 180.9 and 173.5 ± 344.4 μm in IVB and IVZ groups, respectively (P = 0.94). The mean number of injections was higher in the IVB group (4.0 ± 1.8) compared with 1.82 ± 0.8 in the IVZ group (P < 0.0001). The IVZ group had significantly fewer number of visits (P < 0.0001) and longer maximum treatment-free intervals (P = 0.0081).
CONCLUSION:
IVZ appears to be cost-effective with the similar visual outcome and less number of visits in comparison to IVB.
Description
Research Article
Keywords
Branch retinal venous occlusion, bevacizumab, Ziv‑aflibercept, macular edema, optical coherence tomography
Citation
Braimah IZ, Singh SR, Uplanchiwar B, Mansour AM, Chhablani J. Bevacizumab versus ziv‑aflibercept in branch retinal vein occlusion. Indian J Ophthalmol 2019;67:1109-13.